How is Ambulatory Electrocardiogram Predictive of Stroke in Atrial Fibrillation Patients?
Table 1
Baseline characteristics of patients.
Demographics
Stroke group (n = 18)
Control group (n = 192)
t/χ2
values
Men (%)
12 (66.7)
82 (42.7)
3.82
0.05
Age (y)
75.00 (70.25–83.25)
70.00 (62.50–76.00)
−2.30
0.02
Age (%)
<65 (y)
2 (11.1)
52 (27.1)
−2.36
0.02
65–75 (y)
6 (33.3)
86 (44.8)
>75 (y)
10 (55.6)
54 (58.5)
Hypertension (%)
14 (77.8)
74 (38.5)
10.41
<0.01
Diabetes mellitus (%)
6 (33.3)
24 (12.5)
4.26
0.04
CAD (%)
10 (55.6)
92 (47.9)
0.38
0.54
PAD (%)
8 (44.4)
42 (21.9)
3.46
0.06
Heart failure (%)
12 (66.7)
114 (59.4)
0.37
0.55
Antiplatelet (%)
0 (0.0)
50 (26.0)
4.80
0.03
Statins (%)
10 (55.6)
102 (53.1)
0.04
0.84
Anticoagulant (%)
18 (100%)
118 (61.5)
10.71
<0.01
Anticoagulant efficacy (%)
13 (72.22%)
100 (52.08%)
2.69
0.10
Amiodarone (%)
0 (0.0)
4 (2.1)
0.00
1.00
ß-blocker (%)
10 (55.6)
66 (34.7)
3.07
0.08
CHA2DS2-VASc score
6.00 (5.00–7.50)
3.00 (2.00–4.00)
8.90
0.01
CHA2DS2-VASc score (%)
−2.26
0.02
0
0 (0.00)
18 (9.4)
1
0 (0.00)
26 (13.5)
≥2
18 (100.00)
148 (77.1)
Note. CHA2DS2-VASc score included heart failure (1 point), hypertension (1 point) and age 65–74 years (1 point), age ≥75 years (2 points), diabetes (1 point), history of stroke or TIA (2 points), vascular disease (1 point), female (1 point), and the total score is 9. CAD: coronary artery disease; PAD: peripheral artery disease.
